Pfizer Reports Third-Quarter 2026 Financial Results and Raises Full-Year Guidance

Pfizer reported third-quarter 2026 financial results and raised its full-year guidance for total revenue and adjusted diluted earnings per share. CEO Albert Bourla cited commercial momentum and execution, along with progress in the obesity program and recent oncology milestones. The report did not provide specific financial figures or stock-price movements.